International Myeloma Society 2026 Annual Meeting
Interviews and expert commentary from International Myeloma Society 2026 Annual Meeting — study authors and key opinion leaders discuss the findings and their clinical implications.
Zachary Avigan MD; IMS 2026: Predicting Multiple Myeloma Cure: Ultra-Low-Risk Patients Who Have Favorable Outcomes and Can Stop Therapy
GLASGOW, Scotland—Patients who achieved sustained measurable residual disease negativity for more than 24 months had significantly improved survival outcomes and could be categorized as cured. This isthe implication of findings from a retrospective analysis looking at predicting cure in myeloma reported at the International Myeloma Society 2026 Annual Meeting. Sarah Maxwell heard the details from study author Zachary Avigan MD, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Icahn School of Medicine in Mount Sinai Hospital, New York City, USA.